- The report combines individual cases with Shanghai international-service data; these are different kinds of evidence.
- One featured patient was accepted for pre-treatment evaluation before a CAR-T plan was developed—an important sequence often omitted in promotional summaries.
- A reported outcome does not predict eligibility, availability, cost or outcome for another person.
How the report is structured
China Daily's February 2026 story, republished by Shanghai's international-medical-services portal, is not one clinical study. It combines individual patient accounts, comments from hospital staff and sector data about international services. Reading these layers separately is essential. A patient story illustrates a pathway; a hospital statistic describes service activity; neither alone establishes comparative treatment effectiveness for a new patient.
The reported CAR-T pathway
The story follows Oscar Chalupsky, a former South African athlete with high-risk multiple myeloma. It reports that after online communication in November, Ruijin Hospital's international medical department and hematology team accepted him for a pre-treatment evaluation. He then travelled in December for PET-MR, bone-marrow biopsy and T-cell function testing; only after this evaluation was a CAR-T-based plan developed. The sequence is the most useful part of the account: online interest was not treated as approval, and clinical testing preceded the treatment plan.
Why the sequence matters for prospective patients
CAR-T, proton therapy, targeted drugs and other advanced treatments are frequently used as search terms, but they are not travel products. A hospital may need pathology, prior-treatment history, disease status, organ-function information, infection screening, imaging and in-person assessment before it can discuss eligibility. The report does not publish the patient's full clinical criteria, product details, consent process, adverse events, cost, follow-up protocol or long-term outcome; those missing facts prevent a patient from treating the account as a personal recommendation.
International-service capacity reported in Shanghai
The article says Ruijin's international medical department had nearly 100 beds, approximately 150,000 outpatient visits in the previous year, and around 15 percent year-on-year growth in foreign-patient outpatient visits. It also describes Shanghai's 2023 public-hospital international-medical-tourism pilot: 13 hospitals initially joined, then 22, with strengths cited in oncology, cardiovascular disease and neurology. The article further cites more than 300,000 international-service visits in the first half of 2024 and 850 institutions in 57 mainland cities. These are activity and access figures, not a patient-outcome registry.
Other cases in the story
The report includes a Swedish patient who underwent coronary intervention, a Pakistani child treated in a gene-editing research project for thalassemia, an Irish football injury patient, and a French student whose thumb fracture required corrective surgery. These examples cover emergency, chronic, research and scheduled-care contexts. They should not be collapsed into one claim about China. A research project, for example, has different eligibility, consent, risk and follow-up requirements from a routine outpatient visit or an urgent fracture repair.
Cost and speed claims need context
The article gives selected examples: one X-ray visit reportedly took about an hour and cost 130 yuan, and it compares a broad knee-replacement figure with a US figure. Such comparisons can be useful prompts to request itemized estimates, but they are not comparable quotes. Case complexity, hospital type, implant, anesthesia, inpatient days, insurance status, complications, currency date and follow-up all change the final total. The same caution applies to a reported four-day time to surgery; that does not create a general scheduling promise.
A responsible way to act on the report
Use the story to build questions: Will the hospital review my records? Is the proposed treatment standard care, an approved product, a trial or a research project? Which tests are required? How long should I remain nearby? What complications require local management? What is included in the hospital estimate? Who receives discharge records? A written answer from the intended provider, followed by independent clinical advice where appropriate, is more valuable than a social-media or news example.
Sources
See our Sources & Corrections Policy.
Unless explicitly stated, cases discussed here come from public reporting and did not involve our services. This article is general information, not medical, legal or immigration advice.